Evidence map›Paper›PMID 41628253›Full record

ArticleACS synthetic biology2026

Preclinical Evaluation of Synthetic Biology-Driven Engineered

Ahmed Abdalla, Piyush Padhi, Nicholas Bakes, Ross Thyer, Gary Zenitsky, Huajun Jin, Vellareddy Anantharam, Arthi Kanthasamy, Andrew D Ellington, Gregory J Phillips and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ACS synthetic biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Ahmed AbdallaDepartment of Biomedical Sciences, College of Veterinary Medicine, Iowa State University, Ames, Iowa 50011-2042, United States.
Piyush PadhiIsakson Center for Neurological Disease Research, Department of Physiology and Pharmacology, University of Georgia, Athens, Georgia 30602, United States.
Nicholas BakesDepartment of Veterinary Microbiology & Preventive Medicine, Iowa State University, Ames, Iowa 50011-2042, United States.
Ross ThyerDepartment of Chemical and Biomolecular Engineering, Rice University, Houston, Texas 77005-1892, United States.ORCID 0000-0002-0356-5790
Gary ZenitskyIsakson Center for Neurological Disease Research, Department of Physiology and Pharmacology, University of Georgia, Athens, Georgia 30602, United States.
Huajun JinIsakson Center for Neurological Disease Research, Department of Physiology and Pharmacology, University of Georgia, Athens, Georgia 30602, United States.
Vellareddy AnantharamIsakson Center for Neurological Disease Research, Department of Physiology and Pharmacology, University of Georgia, Athens, Georgia 30602, United States.
Arthi KanthasamyIsakson Center for Neurological Disease Research, Department of Physiology and Pharmacology, University of Georgia, Athens, Georgia 30602, United States.
Andrew D EllingtonDepartment of Molecular Biosciences, Center for Systems and Synthetic Biology, University of Texas at Austin, Austin, Texas 78712, United States.ORCID 0000-0001-6246-5338
Gregory J PhillipsIsakson Center for Neurological Disease Research, Department of Physiology and Pharmacology, University of Georgia, Athens, Georgia 30602, United States.
Anumantha G KanthasamyIsakson Center for Neurological Disease Research, Department of Physiology and Pharmacology, University of Georgia, Athens, Georgia 30602, United States.ORCID 0000-0002-6454-4264

Funding

Novel Re-engineered L DOPA Probiotic Therapy for Parkinson's DiseaseR33NS112441 · NINDS · UNIVERSITY OF GEORGIA · PI KANTHASAMY, ANUMANTHA GOUNDER · 2022 to 2023
$765k
Novel Re-engineered L DOPA probiotic therapy for Parkinsons DiseaseR61NS112441 · NINDS · UNIVERSITY OF GEORGIA · PI KANTHASAMY, ANUMANTHA GOUNDER · 2020 to 2020
$387k
NINDS NIH HHS R33 NS112441NINDS NIH HHS R61 NS112441
6 · The paper itself

Abstract

Dopamine deficiency resulting from nigrostriatal dopaminergic neuronal damage manifests as extrapyramidal motor symptoms of Parkinson's disease (PD). Oral tablet dosing of levodopa, administered 3-4 times a day, remains the standard of care due to its tolerability and effectiveness; however, it is prone to deleterious side effects, including off-periods and levodopa-induced dyskinesia after long-term use. Herein, using synthetic biology approaches, we developed and systematically evaluated the feasibility of a probiotic-based live-biotherapeutic system to continuously deliver L-DOPA stably, thereby relieving motor symptoms. Our data demonstrate that our engineered plasmid-based L-DOPA-expressing

Indexed as

Escherichia coliLevodopaParkinson DiseaseProbioticsSynthetic BiologyAnimalsDopamineMiceMice, Inbred C57BLPlasmidsDopamineLevodopaEscherichia coli Nissle 1917L-DOPAlive-biotherapeuticmetabolic engineeringmicrobiomeParkinson’s disease

Identifiers

PMID41628253
PMCPMC12930508

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.